The patient was treated with a single infusion of VX-880 at half the target dose in conjunction with immunosuppressive therapy.
The biotechnology company said it is the first demonstration of a patient with type 1 diabetes achieving robust restoration of islet cell function from such a cell therapy.
"These results from the first patient treated with VX-880 are unprecedented. What makes these results truly remarkable is that they were achieved with treatment at half the target dose," said Bastiano Sanna, chief of cell and genetic therapies. "While still early, these results support the continued progression of our VX-880 clinical studies."
Shares of Vertex Pharmaceuticals are up slightly in early trading.
Price: 181.92, Change: +0.14, Percent Change: +0.08
|Mortgages Applications Rise While Rates Dip, Driving...|
|Baird Adjusts Core & Main's Price Target to $33 From...|
|Credit Suisse Downgrades Banco Santander to Neutral ...|
|US Tech Stocks May Rise Another 20% for 2022, Says W...|
|Taboola.com Renews Partnership with French Publisher...|